Abstract: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid or multimeric structure as well as methods and uses involving the protein, nucleic acid or multimeric structure.

Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimerc structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.

Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.

Abstract: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid or multimeric structure as well as methods and uses involving the protein, nucleic acid or multimeric structure.

Abstract: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus, or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid, or multimeric structure as well as methods and uses involving the protein, nucleic acid, or multimeric structure.

Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.

Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.

Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.

Abstract: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid or multimeric structure as well as methods and uses involving the protein, nucleic acid or multimeric structure.

Abstract: Tetranectin trimerizing polypeptides and fusion proteins including the polypeptides and therapeutic polypeptides and proteins. Trimeric complexes of the polypeptides and fusion proteins. Pharmaceutical compositions of the polypeptides, fusion proteins and the trimeric complexes.

Abstract: Interleuekin-1 receptor antagonists (IL-1Ra) including fusion proteins having a trimerizing domain and an IL-1Ra polypeptide sequence. The fusion proteins are part of trimeric complexes that are used in pharmaceutical compositions for treating diseases mediated by IL-1. Effective treatment of inflammatory diseases, such as rheumatoid arthritis and diabetes, are described.

Abstract: The invention relates to a method of preventing and/or treating a chronic and/or an atopic skin disease by administering an inhibitor of fatty acid oxidation to a patient in a pharmacologically effective amount. Furthermore, the invention relates to the use of at least one inhibitor of fatty acid oxidation for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of a chronic and/or an atopic skin disease.

Abstract: The invention relates to a method of preventing and/or treating a chronic and/or an atopic skin disease by administering an inhibitor of fatty acid oxidation to a patient in a pharmacologically effective amount. Furthermore, the invention relates to the use of at least one inhibitor of fatty acid oxidation for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of a chronic and/or an atopic skin disease.

Abstract: The present invention relates to a papillomavirus T-cell epitope having an amino acid sequence AQIFNKPYW, AGVDNRECI and/or to a functionally active variant thereof, also to their use in diagnostics and therapy.

Abstract: The invention relates to a composition for vaccination against tumors containing at least one tumor cell, which expresses at least one cytikine, chemokine and/or a con-stimulating molecule and an effective quantity of at least one adjuvant. The invention also relates to the used of a composition of this type for a producing a medicament for the treatment or prevention of tumors.

Abstract: The invention relates to the use of a tumor cell for producing a vaccine for the treatment or prophylaxis of tumors in patients, said tumor cell expressing a costimulatory polypeptide and said tumor cell and said patient having non-identical MHC molecules. The invention further relates to the use of a costimulatory polypeptide-expressing tumor cell for producing a vaccine for increasing the lytic activity of NK cells in the treatment or prophylaxis of a tumor in a patient that is allogenic with respect to the tumor cell.

Abstract: The invention relates to the use of at least one cytokine and/or chemokine in the production of a topically acting medicament for treating viral and/or mykotic skin diseases and/or tumoral diseases.

Abstract: The present invention relates to a papillomavirus T-cell epitope having an amino acid sequence ILVPKVSGL (SEQ ID NO: 1), RLVWACVGV (SEQ ID NO: 2), HLFNRAGTV (SEQ ID NO: 3), YLRREQMFV (SEQ ID NO: 4), TLQANKSEV (SEQ ID NO: 5), ILEDWNFGL (SEQ ID NO: 6), SLWLPSEATVYL (SEQ ID NO: 7), NLASSNYFPT (SEQ ID NO: 8), TLTADVMTYI (SEQ ID NO: 9), YLPPVPSKV (SEQ ID NO: 10), YDLQFIFQL (SEQ ID NO: 11), ICWGNQLFV (SEQ ID NO: 12), FYNPDTQRL (SEQ ID NO: 13), MHGDTPTLH (SEQ ID NO: 14), ETTDLYCY (SEQ ID NO: 15), QAEPDRAHYN (SEQ ID NO: 16), SMVTSDAQI (SEQ ID NO: 17), and/or to a functionally active variant thereof, and also to their use in diagnostics and therapy.

Abstract: The present invention relates to a papillomavirus T-cell epitope having an amino acid sequence ILVPKVSGL, RLVWACVGV, HLFNRAGTV, YLRREQMFV, TLQANKSEV, ILEDWNFGL, SLWLPSEATVYL, NLASSNYFPT, TLTADVMTYI, YLPPVPVSKV, YDLQFIFQL, ICWGNQLFV, FYNPDTQRL, MHGDTPTLH, ETTDLYCY, QAEPDRAHYN, SMVTSDAQI, and/or to a functionally active variant thereof, and also to their use in diagnostics and therapy.

Abstract: A medicament for the prevention or treatment of human papillomavirus type 18 (HPV-18)-specific tumor comprising at least one fusion protein of at least one L1 protein and at least one E protein of one or more HPV-18 and, where appropriate, suitable additives and/or excipients, characterized in that the fusion protein is an L1&Dgr;CE7x-y fusion protein, where x is an integer from 1 to 3 inclusive and y is an integer from 61 to 64, in particular 62 to 64, especially 62 or 64.